Manifold Bio is a therapeutics company with a proprietary in vivo multiplexing platform which enables the evaluation of hundreds of antibody designs simultaneously in a single animal experiment. This massive expansion of in vivo data generation powers the company’s AI-guided protein design approach and gives Manifold an unprecedented advantage building its pipeline of tissue-specific medicines. The company is pursuing a pipeline of CNS programs, including Alzheimer's and Parkinson's. Using this platform, Manifold is rapidly expanding a rich portfolio of blood-brain barrier (BBB)-penetrating shuttles against novel targets, along with TfR and CD98, which the company is deploying across internal and partnered CNS programs. Beyond the brain, Manifold is actively pursuing partnerships in other tissues and modalities where delivery remains a bottleneck.